GlassScriptPhysician profile
Debra Lynn Doubek
NPI 1588619910
$5,708.96
in general payments reported to CMS, 2019-2025
40 companies · $790 in 2025
The $790 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $686 · 2020: $619 · 2021: $531 · 2022: $687 · 2023: $1,202 · 2024: $1,194 · 2025: $790.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,185.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $760.49 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $691.35 | 2019-2025 | Evenity, Prolia, Otezla |
| Abbvie INC. | $642.01 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $588.22 | 2019-2025 | |
| Lilly USA, LLC | $460.74 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $312.67 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $292.33 | 2019-2025 | Tezspire, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $175.83 | 2019-2025 | Spravato, Xarelto |
| Abbott Laboratories | $172.58 | 2021-2025 | Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.74 | 2019-2025 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $149.73 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $131.35 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $99.84 | 2019-2023 | Gardasil 9, M-M-R II, Vaxelis |
| Amarin Pharma, INC. | $94.35 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.67 | 2019-2023 | Synjardy, Jardiance |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Doubek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.